PHAR (Pharming Group) EV-to-Revenue : 2.27 (As of May. 25, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Pharming Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pharming Group's enterprise value is $729.6 Mil. Pharming Group's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $320.7 Mil. Therefore, Pharming Group's EV-to-Revenue for today is 2.27.

The historical rank and industry rank for Pharming Group's EV-to-Revenue or its related term are showing as below:

PHAR' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.26 Med: 4.25 Max: 11.97
Current: 2.17

During the past 13 years, the highest EV-to-Revenue of Pharming Group was 11.97. The lowest was 1.26. And the median was 4.25.

PHAR's EV-to-Revenue is ranked better than
76.48% of 995 companies
in the Biotechnology industry
Industry Median: 7.17 vs PHAR: 2.17

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-25), Pharming Group's stock price is $10.38. Pharming Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $4.25. Therefore, Pharming Group's PS Ratio for today is 2.44.

Pharming Group EV-to-Revenue Historical Data

The historical data trend for Pharming Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group EV-to-Revenue Chart

Pharming Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

Get a 7-Day Free Trial

4.46

2.71

3.47

2.90

2.03

Pharming Group Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-Revenue	Get a 7-Day Free Trial															2.74	1.85	1.79	2.03	1.82

Competitive Comparison of Pharming Group's EV-to-Revenue

For the Biotechnology subindustry, Pharming Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pharming Group's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Pharming Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Pharming Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	729.585	/	320.708
	=	2.27

Pharming Group's current Enterprise Value is $729.6 Mil.
Pharming Group's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $320.7 Mil.

Pharming Group (NAS:PHAR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Pharming Group's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	10.38	/	4.254
	=	2.44

Pharming Group's share price for today is $10.38.
Pharming Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.25.

Pharming Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pharming Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

PHGUF:USA PHARM:Netherlands 0QCO:UK PHG:Germany PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.